Health Care · Pharmaceutical Preparations

ARQT Arcutis Biotherapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1787306107 filings
Russell 2000

ARQT at a glance

Arcutis Biotherapeutics, Inc. (ARQT, SEC CIK 1787306) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $376.1 million (up 91.3% from FY2024) and a net loss of $16.1 million. Diluted EPS was -$0.13.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Arcutis Biotherapeutics, Inc. (ARQT) shares worth $1.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Welgus Howard G. on November 16, 2026 of 4,728 shares at $28.16 per share.
  • In the last 90 days, ARQT insiders reported 0 open-market purchases ($0) and 11 open-market sales ($3.3M) on Form 4, a net sale of $3.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$376.1M
+91.3% vs prior year
Insiders · 90 days
0 buys · 11 sells
Net −$3.3M
13F holders
30 funds
$1.6B · −1 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Commercial-stage biopharma specializing in differentiated topical and systemic dermatology treatments targeting immune-mediated diseases
  • New approvals: ZORYVE foam 0.3% for seborrheic dermatitis (FDA Dec 2023), scalp/body plaque psoriasis (FDA May 2025); ZORYVE cream 0.15% for atopic dermatitis (FDA July 2024); ZORYVE cream 0.05% for ages 2-5 (FDA Oct 2025)
  • Strategic shift: Terminated primary care promotion agreement with Kowa (Jan 2026), refocusing commercial efforts internally; expanded global licensing in Greater China, Southeast Asia, Japan
  • Quantitative highlight: Over 8 approvals/commercial launches of ZORYVE formulations across multiple indications from 2023 to 2026; Phase 1 study for acquired ARQ-234 expected Q1 2026
  • Noteworthy fact: Submitted sNDA for ZORYVE cream 0.3% pediatric use down to age 2 with PDUFA June 29, 2026; positive phase 2 topline data for ZORYVE cream 0.05% in infants 3 months–2 years

Risk Factors

  • Regulatory risk: oversight of cybersecurity mandated by SEC guidance on disclosure controls and procedures
  • Operational vulnerability: reliance on VP CT&S with 20 years IT experience for day-to-day cybersecurity risk management
  • Financial risk: potential material impact from cybersecurity incidents reported quarterly to Audit Committee
  • Competitive risk: exposure to evolving cyber threats requiring continuous updates to cybersecurity tools and strategies

Management Discussion & Analysis

  • Revenue $372.1M in 2025, up 123% YoY from $166.5M in 2024; ZORYVE foam up $110.4M, cream 0.15% up $58.4M, cream 0.3% up $35.9M
  • Operating expenses increased; R&D $77.1M in 2025 vs $76.4M 2024 (+1%), SG&A up by $45.2M driven by sales/marketing and compensation
  • Best segment: ZORYVE foam $181.9M in 2025 vs $71.5M 2024 (+154%); worst segment: ZORYVE cream 0.3% with smaller 42% growth
  • Cash, cash equivalents, and marketable securities at $221.3M end 2025 vs $228.6M in 2024; paid down $100M debt principal in Oct 2024
  • Management expects increased R&D and SG&A in 2026 driven by ARQ-234 clinical development and continued ZORYVE commercialization; potential funding needs from equity/debt if cash insufficient

AI summary of the ARQT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
  • Carried-forward risks include potential risks and uncertainties described in the 2025 Annual Report

Management Discussion & Analysis

  • Quarterly product revenue $143.9M, up $44.7M YoY from $99.2M
  • Best performer: ZORYVE foam revenue $75.1M vs $49.8M YoY, up $25.4M
  • ZORYVE cream 0.05% revenue $3.7M, launched October 2025
  • Operating cash flow $33.8M in nine months vs $(31.8)M YoY, cash and securities $259.8M
  • Outlook: R&D and SG&A expected to increase, primarily for ARQ-234 and ZORYVE commercialization

AI summary of the ARQT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results released for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 product revenue $143.9M, up 45% YoY and 11% sequentially, confirming accelerating ZORYVE demand across formulations
  • 2026 sales guidance raised to $535M-$545M from $525M-$540M, signaling stronger commercial visibility
Filed Oct 28, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded from 10 to 11 directors, adding independent Class II director Robert Scott through the 2028 annual meeting
  • Scott brings former AbbVie Chief Medical Officer and Amgen global development leadership experience, strengthening pharmaceutical development oversight

Item EX-99.1: Item EX-99.1

  • Rob Scott, MD appointed to Arcutis’ board effective October 23, 2026
  • Former AbbVie chief medical officer brings experience across approximately 40 new molecular entities and 14 major approvals

Item 7.01: Regulation FD Disclosure

  • Arcutis appointed Dr. Scott, a leadership change potentially affecting strategy and execution
  • Press release dated October 28, 2026, contains the appointment details and should be reviewed for role and transition terms
Filed Aug 5, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Chief Commercial Officer L. Todd Edwards departing August 21, 2026 for external opportunity, without reported disagreement
  • Robert Lisicki appointed interim executive vice president August 17 and interim chief commercial officer August 21

Item EX-99.1: Item EX-99.1

  • Q2 product revenue $129.9M, up 59% YoY and 23% sequentially, confirming accelerating ZORYVE demand
  • 2026 sales guidance raised to $525M–$540M from $480M–$495M, signaling stronger commercial momentum

Item 2.02: Results of Operations and Financial Condition

  • Arcutis announced financial results for quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed earnings release and investor-relevant operating metrics

AI summaries of ARQT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ARQT

Don't miss the next ARQT filing

  • Alerts as it files. A push when ARQT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ARQT, by share count.
  • Ask anything. An AI agent that reads every ARQT filing and answers with sources.

ARQT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Welgus Howard G.SellNov 16, 2026$28.16
Welgus Howard G.MNov 16, 2026-
Welgus Howard G.MNov 16, 2026-
Welgus Howard G.MNov 16, 2026-
Welgus Howard G.MNov 16, 2026$7.51
Welgus Howard G.MNov 16, 2026$6.52
Welgus Howard G.MNov 16, 2026$8.63
Watanabe ToddGNov 13, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$59.6M$196.5M$376.1M
Operating Income--$128.4M-$12.2M
Net Income-$262.1M-$140.0M-$16.1M
Op. Margin--65.3%-3.3%
Net Margin-439.8%-71.3%-4.3%
Balance Sheet
Total Assets-$348.9M$433.0M
Equity$88.7M$157.5M$189.5M
ROE-295.6%-88.9%-8.5%
Per Share
EPS$-3.78$-1.16$-0.13
Cash Flow
Operating CF--$112.2M-$5.6M
CapEx-$143K$686K

Source: XBRL data in Arcutis Biotherapeutics, Inc. (ARQT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ARQT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ARQT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$1.57B
Q2 202631$1.17B
Q1 202629$932.1M
Q4 202525$1.09B
Q3 202524$658.9M
Q2 202525$525.4M
Q1 202525$425.3M
Q4 202421$327.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ARQT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 17, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Nov 4, 2026--
4Oct 28, 2026--
8-KOct 28, 2026Analysis-
4Oct 19, 2026--
4Sep 18, 2026--
4Sep 17, 2026--
4Sep 10, 2026--
4Aug 28, 2026--
4Aug 24, 2026--
4Aug 21, 2026--
4Aug 19, 2026--
SC 13GAug 14, 2026-
4Aug 13, 2026--
SC 13GAug 7, 2026-
4Aug 5, 2026--
4Aug 5, 2026--
10-QAug 5, 2026Analysis
4Aug 5, 2026--
8-KAug 5, 2026Analysis-

Related Health Care companies

All Health Care →

ARQT SEC filings: frequently asked questions

Are ARQT insiders buying or selling?

In the last 90 days, Arcutis Biotherapeutics, Inc. (ARQT) officers, directors and 10% owners reported no open-market purchases and 11 open-market sales worth $3.3 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ARQT stock?

As of September 30, 2026, the largest Arcutis Biotherapeutics, Inc. (ARQT) holders among the 13F filers tracked by SignalX were BlackRock ($506.7 million), State Street Corp ($204.0 million), Morgan Stanley ($140.0 million), Vanguard Capital Management LLC ($132.0 million), Vanguard Portfolio Management LLC ($100.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ARQT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $376.1 million (up 91.3% from FY2024) and a net loss of $16.1 million. Diluted EPS was -$0.13. The figures come from the XBRL data in the 10-K.

What are the main risks in ARQT's latest 10-K?

In the 10-K filed February 25, 2026, Arcutis Biotherapeutics, Inc. (ARQT) flagged: Regulatory risk: oversight of cybersecurity mandated by SEC guidance on disclosure controls and procedures. Operational vulnerability: reliance on VP CT&S with 20 years IT experience for day-to-day cybersecurity risk management. (AI summary of the Risk Factors section.)

What did ARQT report in its latest 8-K?

Arcutis Biotherapeutics, Inc. (ARQT) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results released for quarter ended September 30, 2026.

What are the latest ARQT SEC filings?

Arcutis Biotherapeutics, Inc. (ARQT) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 18, 2026.

What is ARQT's SEC CIK number?

Arcutis Biotherapeutics, Inc. (ARQT)'s SEC Central Index Key (CIK) is 1787306. EDGAR lists every ARQT filing under that number.

Ask anything about ARQT

The research agent reads ARQT's filings, financials, insider trades and 13F holders, then answers with sources.